Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Gastrointestinal Stromal Tumors 13Sarcoma 1Renal Insufficiency 1Penile Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Mastocytosis, Systemic 1Mast Cell Activation Disorders 1Leukemia, Mast-Cell 1Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 51Bevacizumab 23Radiotherapy 16Magnetic Resonance Spectroscopy 16Irinotecan 15Carmustine 12Erlotinib Hydrochloride 10Carboplatin 8Surgical Procedures, Operative 6O(6)-benzylguanine 6Imatinib Mesylate 6Filgrastim 6Cyclophosphamide 6Biopsy 6sargramostim 5aldesleukin 5X-Rays 5Thalidomide 5Phantoms, Imaging 5Chemotherapy, Adjuvant 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5temsirolimus 4Topotecan 4Specimen Handling 4Sirolimus 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Nuclear Medicine Department, Hospital 4Etoposide 4Cisplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × ripretinib × Sarcoma × Clear all
NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡